Breg、PD1、PDL1通過耐受性樹突狀細胞在實驗性自身免疫性腦脊髓炎中的治療作用及機制
發(fā)布時間：2018-07-18 14:33
【摘要】：研究背景及目的意義:多發(fā)性硬化(multiple sclerosis,MS)是中樞神經(jīng)系統(tǒng)慢性炎癥性自身免疫疾病,以腦和脊髓的軸突破壞及髓鞘脫失為主要病理特點。MS患者臨床表現(xiàn)的嚴重程度不一,重者可致身體殘疾,極大程度地降低患者的生活質量。實驗性自身免疫性腦脊髓炎(experimental autoimmune encephalomyelitis,EAE)是MS基礎實驗研究常用的動物模型。樹突狀細胞(dendritic cell,DC)作為專職的抗原提呈細胞,在MS的發(fā)病過程中起重要作用。耐受性樹突狀細胞(tolerogenic dendritic cell,t DC)是一種特殊類型的DC,通過誘導調節(jié)性T細胞(regulatory T cell,Treg)的形成和促進抑炎因子的分泌,對MS具有潛在的治療價值。程序性死亡受體(programmed death 1,PD1)和程序性死亡配體1(programmed death ligand 1,PDL1)屬于B7超家族,通過發(fā)揮負性調節(jié)的作用在MS的發(fā)病過程中起一定的治療作用。調節(jié)性B細胞(regulatory B cell,Breg)是B細胞的一種,可通過分泌抑炎因子在MS的發(fā)病過程中起抑制疾病發(fā)展的作用。1,25(OH)2D3是一種免疫調節(jié)劑,能夠有效誘導t DC(VD3-DC)的形成,并將所誘導VD3-DC回輸給發(fā)病的EAE小鼠后可發(fā)揮一定的治療作用。本實驗課題擬在體外先誘導骨髓來源的單核細胞成為DC,后經(jīng)過具有免疫調節(jié)作用的1,25(OH)2D3誘導形成VD3-DC,檢測正常DC和VD3-DC表面PDL1的表達,后將正常DC和VD3-DC回輸給已發(fā)病的EAE小鼠:(1)觀察回輸治療后EAE小鼠臨床癥狀的變化;(2)檢測脾臟和淋巴結T細胞表面PD1的表達;(3)檢測脾臟和淋巴結B細胞中Breg的比例;(4)采用HE和LFB染色觀察小鼠脊髓內炎性細胞浸潤以及脫髓鞘病變情況。進而探究Breg、PD1、PDL1通過1,25(OH)2D3誘導的VD3-DC在實驗性自身免疫性腦脊髓炎中的治療作用及機制。研究方法:(1)用MOG35-55加完全弗氏佐劑(complete freund's adjuvant,CFA)的混合乳液,經(jīng)背部皮下注入C57BL/6小鼠中,于免疫當天和2天后分別經(jīng)腹腔注射百日咳毒素(pertussis toxin,PTX)建立EAE動物模型;(2)培養(yǎng)基內分別加入白介素-4(interleukin-4,IL-4)和粒細胞巨噬細胞刺激因子(granulocyte-macrophage colony-stimulating factor,GM-CSF)(各10ng/ml)來刺激小鼠股骨和脛骨骨髓來源的單個核細胞誘導DC。誘導DC的同時在其培養(yǎng)基內加入1,25(OH)2D3(10-8M)來誘導形成VD3-DC。然后分別向正常DC、VD3-DC中加入脂多糖(lipopolysaccharide,LPS)刺激24h,促進其成熟,通過流式細胞術檢測DC和VD3-DC表面PDL1的表達;(3)將EAE小鼠分為三組,在DC/VD3-DC誘導的第8天,用MOG抗原孵育4小時后,將MOG抗原洗盡,分別將PBS、DC和VD3-DC經(jīng)尾靜脈回輸給EAE小鼠(EAE小鼠誘導第10、13、16天),觀察各組小鼠臨床癥狀變化;(4)在回輸治療發(fā)病高峰期,分離經(jīng)過回輸治療后的EAE小鼠脾臟和淋巴結細胞,通過流式細胞術檢測細胞表面PD1的表達及Breg的比例;(5)在回輸治療發(fā)病高峰期,分離小鼠脊髓,通過蘇木精-伊紅染色(hematoxylin-eosin staining,HE)和盧克斯快藍染色(luxol fast blue,LFB),觀察對比治療前后EAE小鼠脊髓炎性細胞的浸潤和髓鞘脫失情況。研究結果:(1)根據(jù)我們前期實驗可知,通過相同的實驗方法可以成功誘導出EAE小鼠動物模型和VD3-DC。本實驗通過流式細胞術檢測可知與正常DC相比,VD3-DC表面PDL1的表達增多,且差異具有統(tǒng)計學意義;(2)與PBS對照組相比,DC和VD3-DC回輸給EAE小鼠,可有效減輕其臨床癥狀,且VD3-DC的效果更顯著;(3)與PBS對照組相比,VD3-DC組和DC組脾臟和淋巴結T細胞表面PD1的表達均增加,且有統(tǒng)計學意義;但VD3-DC組和正常DC組之間PD1的表達差異無統(tǒng)計學意義;(4)與PBS對照組相比,VD3-DC組脾臟B細胞表面Breg(CD19+CD5+CD1d+)的比例顯著增加,而正常DC組脾臟B細胞中Breg的比例減少,差異無統(tǒng)計學意義;同時VD3-DC組和正常DC組淋巴結B細胞中Breg的比例均有所增加,但差異無統(tǒng)計學意義;(5)根據(jù)HE和LFB染色可知,與PBS對照組相比,DC和VD3-DC回輸EAE小鼠后,可降低小鼠脊髓炎性細胞浸潤和髓鞘脫失程度,且以VD3-DC作用更顯著。結論:(1)VD3-DC細胞表面PDL1的表達增加;(2)VD3-DC回輸EAE后可有效減輕其臨床癥狀;(3)VD3-DC回輸可增加EAE小鼠脾臟和淋巴結B細胞中Breg的比例以及脾臟和淋巴結T細胞表面PD1的表達;(4)VD3-DC回輸EAE后可顯著降低脊髓內炎性細胞浸潤和髓鞘脫失程度。
[Abstract]:Research background and purpose: multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system. The main pathological features of the brain and spinal cord destruction and myelin loss are the different severity of the clinical manifestations of.MS patients. The heavy persons can cause physical disability and greatly reduce the quality of life of the patients. Experimental autoimmune encephalomyelitis (experimental autoimmune encephalomyelitis, EAE) is a common animal model in MS basic experimental research. Dendritic cell (DC), as a full-time antigen presenting cell, plays an important role in the pathogenesis of MS. The specific type of DC is of potential therapeutic value for MS by inducing the formation of regulatory T cells (regulatory T cell, Treg) and promoting the secretion of anti inflammatory factors. The programmed death receptor (programmed death 1, PD1) and programmed death ligand 1 (programmed death 1) belong to the superfamily, by playing a negative regulatory role. Regulatory B cell (Breg) is a kind of B cell (regulatory B cell, Breg), which can inhibit the development of the disease by secreting anti inflammatory factors in the pathogenesis of MS, and.1,25 (OH) 2D3 is an immune regulator. The EAE mice of the disease can play a certain therapeutic role. This experimental subject intends to induce mononuclear cells derived from bone marrow in vitro to become DC, and then 1,25 (OH) 2D3 induced by immunoregulation to form VD3-DC, to detect the expression of PDL1 on the surface of normal DC and VD3-DC, and then return normal DC and VD3-DC to the infected EAE mice: (1) observation and transfusion. Changes in clinical symptoms of EAE mice after treatment; (2) detection of the expression of PD1 on the surface of T cells in the spleen and lymph nodes; (3) to detect the proportion of Breg in the spleen and lymph node B cells; (4) the infiltration of inflammatory cells and demyelinating lesions in the spinal cord of the mice were observed by HE and LFB staining. Breg, PD1, PDL1 were investigated by 1,25 (OH). The therapeutic effect and mechanism of the experimental autoimmune encephalomyelitis. Methods: (1) a mixed emulsion of complete freund's adjuvant (CFA) and MOG35-55 was injected into the C57BL/6 mice subcutaneously on the back, and the EAE animal model was established by intraperitoneal injection of pertussis toxin (pertussis toxin, PTX) on the day of immunization and 2 days after the immunization. (2) -4 (interleukin-4, IL-4) and granulocyte macrophage stimulating factor (granulocyte-macrophage colony-stimulating factor, GM-CSF) (10ng/ml) were added to the culture base to induce mononuclear cells from the bone marrow of the femur and tibia to induce DC. induced DC, while adding 1,25 (OH) into the culture base to induce the DC. Lead to VD3-DC. and then add lipopolysaccharide (lipopolysaccharide, LPS) to normal DC and VD3-DC to stimulate 24h, promote its maturation and detect the expression of PDL1 on the surface of DC and VD3-DC by flow cytometry; (3) the EAE mice are divided into three groups. After eighth days of DC/VD3-DC induction, they are incubated with MOG antigen for 4 hours. DC through the tail vein to EAE mice (EAE mice induced day 10,13,16) and observe the changes of clinical symptoms in each group. (4) the spleen and lymph node cells of EAE mice were separated after the return transfusion treatment, and the expression of PD1 and the proportion of Breg on the cell surface were detected by flow cytometry; (5) the peak of the treatment was at the peak. During the period, the spinal cord of mice was separated and the infiltration of inflammatory cells and the loss of myelin sheath in EAE mice were observed by hematoxylin-eosin staining (HE) and lux fast blue staining (Luxol fast blue, LFB). The results of the study were: (1) according to our previous experiments, the same experimental method could be successfully induced. The EAE mouse model and VD3-DC. test showed that the expression of PDL1 on the surface of VD3-DC increased in comparison with the normal DC, and the difference was statistically significant. (2) compared with the PBS control group, DC and VD3-DC could effectively reduce the clinical symptoms of EAE mice, and the effect of VD3-DC was more significant; (3) compared with the PBS control group, The expression of PD1 on the surface of T cells of spleen and lymph node in group VD3-DC and DC group increased and had statistical significance, but there was no significant difference in the expression of PD1 between the VD3-DC group and the normal DC group. (4) the proportion of Breg (CD19+CD5+CD1d+) in the spleen B cells in the VD3-DC group was significantly increased compared with that of the PBS control group, and the proportion of the spleen cells in the normal group was proportional to the proportion of the spleen cells in the normal group. The difference was not statistically significant; at the same time, the proportion of Breg in the lymph node B cells of the VD3-DC group and the normal DC group increased, but the difference was not statistically significant. (5) according to HE and LFB staining, compared with the PBS control group, DC and VD3-DC retransfusion of EAE mice could reduce the infiltration of myeloamedullary cells and the degree of myelinating in the mice, and the VD3-DC action was used. Conclusion: (1) the expression of PDL1 on the surface of VD3-DC cells increased; (2) VD3-DC could effectively reduce its clinical symptoms after EAE transfusion; (3) VD3-DC transfusion could increase the proportion of Breg in the spleen and lymph node B cells in EAE mice and the expression of PD1 of the spleen and lymph node T cell surface; (4) the infiltration of inflammatory cells in the spinal cord could significantly decrease the infiltration of inflammatory cells in the spinal cord. And the degree of loss of myelin sheath.
【學位授予單位】：吉林大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R744.51
[Abstract]:Research background and purpose: multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system. The main pathological features of the brain and spinal cord destruction and myelin loss are the different severity of the clinical manifestations of.MS patients. The heavy persons can cause physical disability and greatly reduce the quality of life of the patients. Experimental autoimmune encephalomyelitis (experimental autoimmune encephalomyelitis, EAE) is a common animal model in MS basic experimental research. Dendritic cell (DC), as a full-time antigen presenting cell, plays an important role in the pathogenesis of MS. The specific type of DC is of potential therapeutic value for MS by inducing the formation of regulatory T cells (regulatory T cell, Treg) and promoting the secretion of anti inflammatory factors. The programmed death receptor (programmed death 1, PD1) and programmed death ligand 1 (programmed death 1) belong to the superfamily, by playing a negative regulatory role. Regulatory B cell (Breg) is a kind of B cell (regulatory B cell, Breg), which can inhibit the development of the disease by secreting anti inflammatory factors in the pathogenesis of MS, and.1,25 (OH) 2D3 is an immune regulator. The EAE mice of the disease can play a certain therapeutic role. This experimental subject intends to induce mononuclear cells derived from bone marrow in vitro to become DC, and then 1,25 (OH) 2D3 induced by immunoregulation to form VD3-DC, to detect the expression of PDL1 on the surface of normal DC and VD3-DC, and then return normal DC and VD3-DC to the infected EAE mice: (1) observation and transfusion. Changes in clinical symptoms of EAE mice after treatment; (2) detection of the expression of PD1 on the surface of T cells in the spleen and lymph nodes; (3) to detect the proportion of Breg in the spleen and lymph node B cells; (4) the infiltration of inflammatory cells and demyelinating lesions in the spinal cord of the mice were observed by HE and LFB staining. Breg, PD1, PDL1 were investigated by 1,25 (OH). The therapeutic effect and mechanism of the experimental autoimmune encephalomyelitis. Methods: (1) a mixed emulsion of complete freund's adjuvant (CFA) and MOG35-55 was injected into the C57BL/6 mice subcutaneously on the back, and the EAE animal model was established by intraperitoneal injection of pertussis toxin (pertussis toxin, PTX) on the day of immunization and 2 days after the immunization. (2) -4 (interleukin-4, IL-4) and granulocyte macrophage stimulating factor (granulocyte-macrophage colony-stimulating factor, GM-CSF) (10ng/ml) were added to the culture base to induce mononuclear cells from the bone marrow of the femur and tibia to induce DC. induced DC, while adding 1,25 (OH) into the culture base to induce the DC. Lead to VD3-DC. and then add lipopolysaccharide (lipopolysaccharide, LPS) to normal DC and VD3-DC to stimulate 24h, promote its maturation and detect the expression of PDL1 on the surface of DC and VD3-DC by flow cytometry; (3) the EAE mice are divided into three groups. After eighth days of DC/VD3-DC induction, they are incubated with MOG antigen for 4 hours. DC through the tail vein to EAE mice (EAE mice induced day 10,13,16) and observe the changes of clinical symptoms in each group. (4) the spleen and lymph node cells of EAE mice were separated after the return transfusion treatment, and the expression of PD1 and the proportion of Breg on the cell surface were detected by flow cytometry; (5) the peak of the treatment was at the peak. During the period, the spinal cord of mice was separated and the infiltration of inflammatory cells and the loss of myelin sheath in EAE mice were observed by hematoxylin-eosin staining (HE) and lux fast blue staining (Luxol fast blue, LFB). The results of the study were: (1) according to our previous experiments, the same experimental method could be successfully induced. The EAE mouse model and VD3-DC. test showed that the expression of PDL1 on the surface of VD3-DC increased in comparison with the normal DC, and the difference was statistically significant. (2) compared with the PBS control group, DC and VD3-DC could effectively reduce the clinical symptoms of EAE mice, and the effect of VD3-DC was more significant; (3) compared with the PBS control group, The expression of PD1 on the surface of T cells of spleen and lymph node in group VD3-DC and DC group increased and had statistical significance, but there was no significant difference in the expression of PD1 between the VD3-DC group and the normal DC group. (4) the proportion of Breg (CD19+CD5+CD1d+) in the spleen B cells in the VD3-DC group was significantly increased compared with that of the PBS control group, and the proportion of the spleen cells in the normal group was proportional to the proportion of the spleen cells in the normal group. The difference was not statistically significant; at the same time, the proportion of Breg in the lymph node B cells of the VD3-DC group and the normal DC group increased, but the difference was not statistically significant. (5) according to HE and LFB staining, compared with the PBS control group, DC and VD3-DC retransfusion of EAE mice could reduce the infiltration of myeloamedullary cells and the degree of myelinating in the mice, and the VD3-DC action was used. Conclusion: (1) the expression of PDL1 on the surface of VD3-DC cells increased; (2) VD3-DC could effectively reduce its clinical symptoms after EAE transfusion; (3) VD3-DC transfusion could increase the proportion of Breg in the spleen and lymph node B cells in EAE mice and the expression of PD1 of the spleen and lymph node T cell surface; (4) the infiltration of inflammatory cells in the spinal cord could significantly decrease the infiltration of inflammatory cells in the spinal cord. And the degree of loss of myelin sheath.
【學位授予單位】：吉林大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R744.51
【相似文獻】
相關期刊論文 前10條
1 李繼紅,李如琴;樹突狀細胞的分化發(fā)育以及在抗感染中的作用[J];山西臨床醫(yī)藥;2001年05期
2 孔令平,劉妍,黃志勤;樹突狀細胞的特性與分化發(fā)育[J];贛南醫(yī)學院學報;2003年02期
3 趙謹 ,王心;樹突狀細胞(dendritic cells)[J];日本醫(yī)學介紹;2005年06期
4 張臨友,郭松,楊寶峰;激素與樹突狀細胞[J];國外醫(yī)學(移植與血液凈化分冊);2005年05期
5 吳萍萍;杜曉英;劉書遜;陳榮軍;壽張飛;陳江華;;不同來源人樹突狀細胞的培養(yǎng)誘導及鑒定[J];浙江醫(yī)學;2007年09期
6 ;封面圖片——樹突狀細胞[J];中國廠礦醫(yī)學;2009年04期
7 張錦X,陳海濱,謝慶東,王駿;人血樹突狀細胞形成細胞簇功能的體外觀察[J];解剖學雜志;1997年02期
8 曹華,張銳,裴雪濤;樹突狀細胞的生物學特性及臨床應用[J];基礎醫(yī)學與臨床;2000年06期
9 王黎明,劉艷榮,李金蘭,常艷,付家瑜,高暉,陳珊珊;人慢性粒細胞白血病樹突狀細胞的培養(yǎng)和鑒定[J];中華醫(yī)學雜志;2000年05期
10 夏青,張學軍;真皮樹突狀細胞與皮膚病[J];國外醫(yī)學.皮膚性病學分冊;2000年02期
相關會議論文 前10條
1 蔣應明;萬濤;陳國友;夏大靜;周向陽;修方明;張意;曹雪濤;;樹突狀細胞來源的鈣粘著相關蛋白新基因的克隆、表達及功能研究[A];中國免疫學會第四屆學術大會會議議程及論文摘要集[C];2002年
2 王勝軍;王麗莉;李堅;許化溪;;肺癌患者胸水中樹突狀細胞的誘導和初步鑒定[A];中國免疫學會第四屆學術大會會議議程及論文摘要集[C];2002年
3 徐克成;牛立志;郭子倩;張德春;左建生;;樹突狀細胞及其在癌腫治療中應用[A];中國中西醫(yī)結合學會第十五次全國消化系統(tǒng)疾病學術研討會論文匯編[C];2003年
4 何廣勝;邵宗鴻;和虹;劉鴻;施白;潔均;曹燕然;Q，
本文編號：2132203
本文鏈接：http://sikaile.net/yixuelunwen/shenjingyixue/2132203.html
最近更新
教材專著
